Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Stoke Therapeutics Inc
(NQ:
STOK
)
12.05
+0.40 (+3.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Stoke Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 21, 2023
Via
Benzinga
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Analyst Expectations for Stoke Therapeutics's Future
June 08, 2023
Via
Benzinga
Analyst Ratings for Stoke Therapeutics
June 08, 2023
Via
Benzinga
12 Analysts Have This to Say About Stoke Therapeutics
May 23, 2023
Via
Benzinga
Where Stoke Therapeutics Stands With Analysts
May 23, 2023
Via
Benzinga
Stoke Therapeutics: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
What 7 Analyst Ratings Have To Say About Stoke Therapeutics
April 26, 2023
Via
Benzinga
Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know
March 07, 2023
Via
Benzinga
6 Analysts Have This to Say About Stoke Therapeutics
March 07, 2023
Via
Benzinga
Adobe And 2 Other Stocks Insiders Are Selling
May 04, 2023
The S&P 500 closed lower on Wednesday after the Fed increased rates by 25 basis points, as widely expected. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 04, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
May 03, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
April 25, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
March 15, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 06, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Expert Ratings for Stoke Therapeutics
January 11, 2023
Via
Benzinga
Stoke Therapeutics Earnings Perspective: Return On Capital Employed
December 26, 2022
Via
Benzinga
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
February 27, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
January 09, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Yum! Brands To Rally Around 20%? Here Are 10 Other Price Target Changes For Monday
December 05, 2022
Via
Benzinga
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
December 02, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Friday
December 02, 2022
On Friday, 72 companies hit new 52-week lows.
Via
Benzinga
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
November 29, 2022
From
Stoke Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
November 22, 2022
During Tuesday's trading, 160 companies set new 52-week lows.
Via
Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
November 17, 2022
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
November 15, 2022
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.